1. Online consultations via Telehealth: We connect patients with healthcare professionals through virtual consultations, allowing them to discuss weight loss goals, medical history, and other factors without needing to visit a physical clinic.

2. Personalized plans: Based on the consultations, Midwest 360 Wellness providers can develop personalized weight loss plans tailored to the specific needs, preferences, and lifestyle of each patient.

3. Prescription medications: If appropriate, our medical providers can prescribe weight loss medications, such as GLP-1 receptor agonists or other FDA-approved options. 

4. Ongoing support: Midwest 360 Wellness provides ongoing support and follow-up consultations with your prescribing provider to monitor progress, address any concerns, and make adjustments to the weight loss plan as needed.

5. Transparency: There are no hidden fees, no monthly fees, and no cancellation fees. You may opt out of the program at any time, by simply letting your provider know. 

Tirzepatide, is in a class of medications called GLP-1 agonists, which mimic hormones involved in blood sugar control and appetite. It’s taken via injection once a week and has been shown to decrease how much food people eat and increase how much energy they burn. 

Tirzepatide has an element that mimics a hormone called GIP, which can reduce appetite and improve how well your body breaks down sugar and fat. The elements of the drug “work together to improve how the brain sees weight, which leads to weight loss and better blood sugar regulation.”  Tirzepatide mimics the GLP-1 hormone and the GIP hormone. The GIP hormone can also trigger insulin creation and sensations of fullness. This means Tirzepatide may offer an extra weight loss boost, and some find it to have fewer GI side effects when using Tirzepatide compared to Semaglutide.

Both Tirzepatide and Semaglutide are highly effective in helping people lose weight, decreasing appetite, and “shutting off the brain-gut chatter,” thus decreasing cravings for foods.

People are typically able to lose 15-21% of their body weight

• Common side effects are: nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distention, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and nasopharyngitis

• GLP’s can cause a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. Monitor the effects of oral medications concomitantly administered with GLP’s.  If you are having surgery, let your doctor know you are on a GLP. 

Just click book an appointment and enter your email on that page. You will receive a link to access our booking page on our patient portal. Pick a time that works for you, and your telehealth appointment will be scheduled.  This is a face to face video chat, treat it as you would any doctors appointment. Please don’t hesitate to reach out via email or phone with any questions or concerns you may have before or after you book.

Do Not Use if you have:

Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Pregnant or breastfeeding

If you are diabetic, please contact your doctor.

Past suicidal ideation, suicide attempt, uncontrolled psychiatric disorders. 

Allergies to GLP-1 medications.

History of pancreatitis or severe alcohol abuse

Renal impairment 

Age less than 18 years old

Precautions

Cardiovascular: Sustained increases in resting heart rate have occurred; monitoring is recommended, and discontinuation may be necessary

Gastrointestinal: Acute and chronic pancreatitis has been reported; monitoring is recommended and discontinue use if suspected. If confirmed, do not restart therapy. 

Acute gallbladder disease, including cholelithiasis and cholecystitis, has occurred; substantial or rapid weight loss may increase risk; appropriate medical management may be necessary.

Psychiatric: Suicidal behavior and ideation have occurred during the use of other drugs used for weight management. 

Immunologic: Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with glucagon-like peptide 1 (GLP-1) receptor agonists. 

Renal: Acute kidney injury and worsening of chronic renal failure, sometimes requiring dialysis, have been reported in patients receiving GLP-1 receptor agonists; monitoring is recommended, especially in patients reporting severe adverse gastrointestinal reactions